Navigation Links
Safety of Labor-Delaying Drugs Questioned
Date:3/6/2009

The dilemma, researchers say, is whether or not to treat at all

FRIDAY, March 6 (HealthDay News) -- Certain drugs used to delay preterm labor can cause serious complications in women, a European study finds.

Doctors use tocolytic drugs to delay labor for up to 48 hours. In this way, they gain time to allow steroids to hasten fetal lung development. These delays also enable the expectant mother to be transferred to a medical facility with a neonatal intensive care unit, according to background information in the study.

The most widely used tocolytic drugs include beta agonists and nifedipine (which relax smooth muscles, including the uterus), and atosiban and indometacin (which inhibit hormones involved in labor), according to the study. However, the use of these drugs is controversial, because it's not clear whether tocolysis is safe for both mother and baby.

The researchers analyzed the rate of serious complications in 1,920 women treated with tocolytic drugs for preterm labor at 28 hospitals in the Netherlands and Belgium. Atosiban was the most commonly used drug (42 percent), followed by nifedipine (34 percent), beta agonists (14 percent), and indometacin (8 percent).

The overall incidence of adverse effects was 0.7 percent, but combined or single treatment with a beta agonist led to a higher incidence of serious drug reactions. There were no reports of serious reactions when women received atosiban or indometacin.

Combined or single treatment with beta agonists should be discouraged, concluded the researchers. They also recommended further trials to test the safety and effectiveness of nifedipine and atosiban.

In an accompanying editorial, the researchers said their study is a reminder that the decision to use tocolysis shouldn't be taken lightly.

"After 30 years of research, we still do not know whether tocolysis benefits the fetus, so the choice of which drug to use remains a secondary question. The real dilemma is whether or not we should treat at all," they wrote. The long-held belief that "keeping the baby inside longer must be a good thing" needs to be reevaluated, they said.

The study was published March 6 online in the BMJ.

A study released last year found that nifedipine was no more effective than placebo at preventing preterm labor. The U.S. study, which included 71 women, was published in the journal Obstetrics & Gynecology.

More information

The U.S. National Institute on Child Health and Human Development has more about preventing preterm birth.



-- Robert Preidt



SOURCE: BMJ, news release, March 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. AdvaMed Available for Comment on Medical Device Safety Act
2. AdvaMed Response to the Medical Device Safety Act
3. bioPoint(TM) PID Wristband Software Improves Patient Identification Accuracy and Safety
4. New Esco White Papers Document Hydrogen Peroxide Decontamination of Biological Safety Cabinets
5. Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment
6. Zebra Technologies Introduces New Soft Infant Wristbands for Improved Safety and Comfort
7. Travel Safety Can Be a Passport to Good Health
8. Main U.S. Toxics Law Failing to Ensure Safety of Thousands of Chemicals
9. Johns Hopkins safety team works to eliminate bloodstream infections in the nation and the world
10. Governor Rendell Forms Food Safety Council to Protect Public Health, Food Supply
11. Switch to Daylight Savings Time Will Launch First Annual Sedation Dentistry Safety Week Hosted by DOCS Education
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Safety of Labor-Delaying Drugs Questioned
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of ... of an injury, patients must find the one that works for them. When an ... created a machine that worked and decided to share it with others. , He ...
(Date:12/2/2016)... ... ... Mediaplanet is proud to announce the launch of its ... therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage their ... the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This is ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Sourced from ... has some unique properties including its unmatched natural purity of just 6 ppm TDS ... and crisp. , Nothing Water has been available in several ShopRite and FoodTown stores ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, ... raised $6.0 million in an initial round of funding. The round was led ... their caregivers can receive far better care through the application of the best ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative ... National Family Partnership and the Drug Enforcement Administration as part of the National Red ... 10 winning schools who decorated their campuses with this year’s Red Ribbon Week theme: ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016  PipelineRx, a leading medication management technology ... demonstrations of its SaaS-based telepharmacy platform, PowerGridRx™ ... 2016 Midyear Clinical Meeting and Exhibition, December 5-7 ... nearly 300 hospital clients nationally, the Company is ... to dramatically improve pharmacy operations, enhance patient safety, ...
(Date:12/2/2016)... , Dec. 2, 2016  Eli Lilly and ... financial guidance for 2017 and provide updated financial guidance ... also conduct a conference call on that day with ... company,s financial guidance. The conference call will ... general public can access a live webcast of the ...
(Date:12/2/2016)... MARLBOROUGH, Mass. , Dec. 2, 2016 ... announced a definitive agreement to acquire certain manufacturing assets ... NVCN ) (TSX: NVC) advanced biological tissue business, as ... a total of $75 million in cash. The Neovasc ... heart valves, including the Boston Scientific Lotus™ Valve System. ...
Breaking Medicine Technology: